Soleno Therapeutics, Inc. (SLNO)

Market Cap	1.94B
Revenue (ttm)	n/a
Net Income (ttm)	-131.16M
Shares Out	43.12M
EPS (ttm)	-3.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,230
Open	45.01
Previous Close	45.18
Day's Range	44.41 - 45.37
52-Week Range	35.70 - 60.92
Beta	-1.53
Analysts	Strong Buy
Price Target	74.83 (+66.27%)
Earnings Date	Nov 6, 2024

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, Califor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO
• Website: https://soleno.life

Analyst Forecast

According to 6 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is $74.83, which is an increase of 66.27% from the latest price.

Price Target

$74.83

(66.27% upside)

Analyst Consensus: Strong Buy